The trajectory of Sildenafil presents a complex case for observers in the pharmaceutical sector. While initially a blockbuster success, generating vast sums, the intellectual property expiration and the subsequent arrival of generic versions have drastically changed income. This poses questions about the future sustainability of related medicati… Read More